BRUSSELS, Belgium - Irish water treatment company OxyMem has secured a prize for its Membrane Aerated Biofilm Reactor (MABR) technology at the Most Innovative European Biotech SME awards.
The awards recognise small and medium sized enterprises in Europe that have developed novel ways of meeting our societal, technical, and environmental problems through the application of biotechnology.
In total, a 41 companies from 13 countries applied for this year’s Most Innovative European Biotech SME awards.
OxyMem won the ‘Industrial or White Biotech Category’, with runners up including Danish biotech start-up Biosynthia and Finnish company, MetGen.
Earlier this year the Irish company secured investment from the Dow Chemical company (read story).
Conventional wastewater treatment consumes large amounts of electricity due to its reliance over the last 100 years on bubble diffusion, which will typically suffer energy losses of 65-70% in the process.
OxyMem claims that its MABR technology is 75% more efficient, as the system does not use bubbles to deliver oxygen.
Tom Saylor, Chairman of the EuropaBio SME Platform: “European biotech companies are at the leading edge of innovation worldwide as represented by the winners and runners-up of this competition. However, our biotech SMEs continue to face a challenging environment in terms of finance, regulatory policy and legislative rules. It is, therefore, important to offer a platform for public recognition to demonstrate their outstanding work and benefits to society, and to recognise the importance of sound European policy and business environment for such enterprises to thrive.”